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ABSTRACT
Immediate administration of adequate antibiotic therapy is critical to improving survival in patients
with ventilator-associated pneumonia (VAP). At the same time, appropriate antimicrobial stewardship
includes not only limiting the use of inappropriate agents in patients with VAP, but also, improving our
ability to diagnose and exclude infection in the intensive care unit (ICU). Particular obstacles include: the
differentiation between colonisation and infection of the lower respiratory tract; the interpretation of
non-speciﬁc clinical signs and symptoms suggestive of lung infection; and the optimal use of antibiotics
in the ICU. ‘Clinical’ management of VAP involves the initiation of empirical therapy based on risk-
factors, qualitative microbiological tests and local bacterial resistance patterns, and its subsequent
adjustment according to culture results. ‘Bacteriological’ management with direct examination and
quantitative culturing of specimens obtained using ﬁbreoptic bronchoscopy, e.g., bronchoalveolar
lavage and ⁄ or by protected specimen brush techniques, helps to better direct initial antibiotic therapy, as
well as to conﬁrm the diagnosis of VAP.
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INTRODUCTION
Ventilator-associated pneumonia (VAP) remains
an important cause of morbidity and mortality
despite advances in antimicrobial therapy, better
supportive care modalities and the use of pre-
ventive measures [1,2]. However, for more than
15 years the management of VAP has been a
controversial subject [3,4], even though the clin-
ical objectives of physicians responsible for treat-
ing patients with suspected VAP are well
accepted and clear. These objectives are to:
• accurately identify patients with true lung
infection;
• determine the aetiological pathogen(s) when
pneumonia is present, in order to deliver
optimised, targeted therapy based on pathogen
susceptibility;
• identify patients with extra-pulmonary infec-
tion;
• withhold and ⁄ or withdraw antibiotics in
patients without bacterial infection [1,2,5–7].
The debate on the best strategy for VAP
management is the result of differences in the
analysis of three important factors: (i) the differ-
entiation between colonisation and infection of
the lower respiratory tract; (ii) the interpretation
of clinical signs and symptoms suggestive of lung
infection; and (iii) the optimal use of antibiotics in
the intensive care unit (ICU).
COLONISATION VS. INFECTION
The ﬁrst major obstacle to be confronted in the
diagnosis of VAP is the fact that, unlike the
situation in patients developing community-
acquired pneumonia, the presence of bacteria in
the lower airways of intubated patients is not a
sufﬁcient reason to diagnose true lung infection
[1]. Most cases of VAP seem to result from the
aspiration of potential pathogens that have colo-
nised the oropharyngeal airways. Intubation faci-
litates the entry of bacteria into the lung by the
pooling and leakage of contaminated secretions
around the endotracheal cuff [1,2]. The tracheo-
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bronchial tree and the oropharynx of mechanic-
ally ventilated patients are frequently colonised
by enteric Gram-negative bacilli. However, the
relationship between tracheal colonisation and
lung infection remains unclear [1]. For example,
in a landmark study, Johanson et al. demonstra-
ted that only 23% of colonised patients subse-
quently developed nosocomial pneumonia [8]. In
a more recent series, VAP occurred in 4 ⁄ 10
patients colonised with Pseudomonas aeruginosa
at intubation, and in 4 ⁄ 31 patients with
ICU-acquired colonisation with this organism [9].
CLINICAL SIGNS AND SYMPTOMS
The second major difﬁculty in diagnosing VAP is
that the presence of signs suggestive of pneumonia
in non-ICU patients is too non-speciﬁc to be of
diagnostic value in ventilated patients [1,2]. The
diagnosis of pneumonia is usually based on the
presence of fever, leukocytosis and new or wor-
sening lung inﬁltrates on the chest radiograph.
These clinical and radiological signs are reliable
diagnostic criteria with which to determine whe-
ther community-acquired pneumonia is present in
a patient admitted to the emergency room or the
ICU. In contrast, systemic signs of infection or lung
inﬁltrates are frequently caused by other factors in
hospitalised, ventilator-dependent patients. Fever
and leukocytosis may be the consequences of any
condition that leads to the release of cytokines,
including those of non-infectious origin, such as
drug-related fever, pulmonary oedema or infarc-
tion, and non-pulmonary infections, such as vas-
cular catheter infection, gastrointestinal infection,
urinary tract infection, post-operative fever, sinus-
itis or wound infection. Meduri et al. conﬁrmed
the presence of lung infection in only 42% of
patients with clinically suspected VAP, and the
frequent occurrence of multiple infectious or non-
infectious processes [10].
Similarly, when inﬁltrates are present on chest
radiograph, it is difﬁcult to differentiate between
cardiogenic pulmonary oedema, atelectasis, pul-
monary contusion, infarction and pneumonia in
patients treated with mechanical ventilation, espe-
cially as such patients are frequently admitted to
the ICU because of the presence of severe pulmon-
ary disease. Finally, purulent secretions are almost
inevitably found in patients receiving prolonged
mechanical ventilation and do not speciﬁcally
indicate the presence of bacterial pneumonia.
STRATEGIES FOR ANTIBIOTIC USE
The third major problem in the management of
patients suspected of having VAP concerns the
optimal use of antibiotics in the ICU. Most
epidemiological investigations have clearly dem-
onstrated that the indiscriminate administration
of antimicrobial agents to patients in the ICU has
both immediate and long-term consequences that
contribute to the emergence of multiresistant
pathogens, increase the risk of severe superinfec-
tions associated with potentially increased mor-
bidity and mortality, and of antibiotic-related
toxicity, and increase overall healthcare costs [11].
Patient survival may improve if VAP is treated
rapidly and correctly, i.e., with antibiotics to which
the causal organism is sensitive and which are
administered at an optimal dosage via the correct
route of administration. Conversely, studies using
multivariate analysis have clearly demonstrated
that delayed and ⁄ or inappropriate initial antibiotic
therapy is strongly associated with fatality in
critically ill patients with infections, including
VAP [12,13]. More precisely, the prognostic
importance of the appropriateness of initial anti-
microbial therapy has been underlined in many,
mostly recent, studies. For example, Kollef et al.
showed that an inadequate antibiotic regimen
initiated before the results of cultures from respir-
atory secretions were obtained was associated
with a hospital mortality rate (42.0%) greater than
that for an antibiotic regimen that provided
adequate antimicrobial coverage of all identiﬁed
pathogens from cultures (17.7%; p <0.001) [12].
Unfortunately, two factors appear to render the
choice of antibiotics particularly difﬁcult in critic-
ally ill patients with VAP. First, VAP is likely to
result from highly resistant organisms, especially
in patients who were previously treated with
antibiotics and ⁄ or in cases of pneumonia occurring
more than 7 days after the initiation of mechanical
ventilation [14]. Second, multiple organisms are
frequently cultured from the pulmonary secre-
tions of patients considered to have pneumonia,
especially when the sampling technique is not
speciﬁc enough to differentiate between colonising
and infecting pathogens. Therefore, no ‘magic
bullet’ exists to cover all the microorganisms
potentially responsible for VAP.
Numerous high-quality studies have assessed
different diagnostic techniques in the setting of
suspected VAP, with the determination of their
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operative indices being compared with human or
animal histopathological and ⁄ or bacteriological
deﬁnitions of pneumonia. In contrast, only a few
studies have correctly evaluated strategies, inclu-
ding diagnostic and therapeutic approaches, with
a view to answering these two major questions:
• Does the application of the strategy result in a
beneﬁt for the patient?
• Does the application of the strategy reduce
and ⁄ or control the overuse of antimicrobial
agents?
Two diagnostic algorithms can be used to try to
answer to these questions in the case of suspected
VAP [1,2,5–7,15].
Clinical approach to management
One option is to treat every patient clinically
suspected of having a pulmonary infection with
new antibiotics, even when the likelihood of
infection is low (Fig. 1) [2]. Qualitative microbio-
logical testing (e.g., Gram’s stain) is performed to
identify possible pathogens, and antimicrobial
therapy is adjusted at 48–72 h according to an
assessment of both clinical response and culture
results.
This clinical approach to VAP management has
two potential advantages: ﬁrst, no specialised
microbiological techniques are required; and sec-
ond, the risk of missing a patient who needs
antimicrobial treatment is minimal, at least when
all suspected patients are treated with new antibi-
otics. However, such a strategy leads to overesti-
mation of the incidence of VAP, because
tracheobronchial colonisation and non-infectious
processes mimicking the infection are included as
diagnostic criteria. Qualitative endotracheal aspir-
ate cultures contribute indisputably to the diagno-
sis of VAP onlywhen they are completely negative
for a patient with no modiﬁcation of prior antimi-
crobial treatment. In such a case, the negative
predictive value is very high and the probability of
the patient having pneumonia is close to zero.
Bacteriological approach to management
Concerns about the inaccuracy of clinical
approaches to VAP recognition, and the fact that
such a strategy could not possibly avoid over-
prescription of antibiotics in the ICU, led numer-
ous investigators to postulate that specialised
diagnostic methods could improve the system
for identiﬁcation of patients with true VAP,
thereby facilitating decisions concerning treat-
ment with antibiotics and improvement of clinical
outcome. Such methods include direct examina-
tion and quantitative culturing of specimens
obtained using ﬁbreoptic bronchoscopy, partic-
ularly bronchoalveolar lavage and ⁄ or protected
specimen brush techniques [1,2]. Such specimens
must be obtained before current antibiotic therapy
is started or before a change in antibiotic therapy.
When culture results are available, they allow the
precise identiﬁcation of the offending organisms
and their susceptibility patterns, and hence can
guide a modiﬁcation of antibiotic therapy in
conjunction with a reassessment of clinical reso-
lution. Fig. 2 illustrates how this bacteriological
approach can be integrated into a general protocol
for the diagnosis and management of ICU-
acquired infections.
In a randomised trial involving 413 patients
with suspected VAP, bronchoscopic management
signiﬁcantly reduced 14-day mortality and sepsis-
related organ dysfunction when compared with
clinical management based on clinical criteria,
non-quantitative isolation of organisms from
endotracheal aspirates and clinical practice guide-
lines [16]. Moreover, bronchoscopic management
was associated with signiﬁcantly decreased anti-
biotic use, quantiﬁed as a greater number of
antibiotic-free days at 14 and 28 days.
Obtain immediate endotracheal
aspirate specimen before 
starting or changing existing antibiotics
Clinical features
suggesting VAP
Start empirical antibiotics
immediately using ATS-IDSA guidelines
Adjust antibiotics
based on culture results
and clinical response
Stop
antibiotics
No further 
investigation;
observe
Positive
cultures
YES
NO
NO
YES
Fig. 1. Clinical strategy applied to patients with clinical
suspicion of ventilator-associated pneumonia (VAP).
Reproduced with permission from Chastre & Fagon [1].
ATS, American Thoracic Society; IDSA, Infectious Diseases
Society of America.
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Selection and de-escalation of antibiotic therapy
for VAP
There is a clear consensus that empirical anti-
biotic therapy must be initiated promptly in
patients with VAP [1,2,6,7]. VAP is commonly
caused by P. aeruginosa, Acinetobacter spp., Kleb-
siella pneumoniae, Enterobacter, or Staphylococcus
aureus (including methicillin-resistant S. aureus).
Since pathogens associated with inappropriate
initial therapy are usually antibiotic-resistant
strains of these pathogens, patients at risk of
infection with these organisms should initially
receive a combination of agents providing a
very broad spectrum of coverage [1,2,5,6,7,15].
Despite these general aetiological trends, the
spectrum of typical pathogens causing VAP
varies among ICUs. Therefore, initial empirical
therapy should be selected according to a detailed
and up-to-date understanding of the local pat-
terns of organism prevalence and resistance,
together with an evaluation of patient risk-factors
for infection as a multiresistant pathogen. Current
guidelines from the American Thoracic Soci-
ety ⁄ Infectious Disease Society of America [2]
deﬁne risk-factors for infection as any of a
constellation of multidrug-resistant pathogens.
These factors include antimicrobial therapy in
the preceding 90 days, current hospitalisation of
‡5 days, high local prevalence of resistance, and
immunosuppressive disease or therapy [2]. In
contrast, the ‘Tarragona approach’ to empirical
VAP therapy differentiates among P. aeruginosa,
methicillin-resistant S. aureus and Acinetobacter
according to differences in the speciﬁc risk-fac-
tors, virulence and susceptibility patterns of these
species [5,6,7,15] (Fig. 3).
Detailed recommendations for speciﬁc antibiotic
regimens forVAP therapy are published elsewhere
[2] and are beyond the scope of this review.
Generally, the choice of antibiotics and dosages
for the treatment of VAP should take into account
Immediate sampling of distal airways
by BAL/PSB before changing existing antibiotics
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suggesting VAP
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examination
Bacteria
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and local epidemiology 
Adjust antibiotics
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Continue or adjust
antibiotics; look for
another infection(s)
No further 
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Adjust antibiotics
based on culture results
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based on ATS/IDSA guidelines 
Continue or adjust
antibiotics; look for 
another infection(s)
Observe;
look for another 
infection(s)
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quantitative
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NO
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Fig. 2. Bacteriological strategy applied to patients with clinical suspicion of ventilator-associated pneumonia (VAP).
Reproduced with permission from Chastre & Fagon [1]. ATS, American Thoracic Society; BAL, bronchoalveolar lavage;
IDSA, Infectious Diseases Society of America; PSB, protected specimen brush.
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the pharmacokinetic aspects speciﬁc to the critical
care setting. For example, drug penetration to the
lung and optimisation of the dose should be
considered in patients with severe sepsis or shock.
Under-dosage may occur because of the increased
volume of distribution that occurs in hyperdynam-
ic conditions and the increase in renal blood ﬂow
during the early phases of sepsis, whereas toxicity
may occur because of a drop in renal clearance
caused by further renal impairment [5,15].
Initial broad-spectrum antibiotic therapy for
VAP should be narrowed or ‘de-escalated’, where
possible, according to an evaluation at 48–72 h of
both the clinical response to therapy and the results
of microbiological investigations—ideally quanti-
tative, bronchoscopically acquired cultures (Fig. 4)
[2,6,7]. Among the clinical signs of infection, the
resolution of core fever and of hypoxaemia offers a
useful guide to response and is easily monitored
[6,7].
Clinical suspicion of 
VAP
li i l i i  f 
Empiric therapyEmpirical therapyMicrobiological featuresi r i l i l f t r
Cultureslt r Direct stainir t t i
Late onset or risk 
factors
t  t r ri  
f t r
Early
onset
rl
t
Endogenous
florafl r
Non-anti-
Pseudomonas
aeruginosa
antibiotics
- ti-
r i
ti i ti
Gram-
positive
r -
iti
Gram-
negative
r -
ti
Risk of MRSA?i  f 
Yes No
Anti-MRSA coverageti-  r
Risk of
Acinetobacter baumannii?
i  f
i t t r ii
Yes No
Carbapenemr
Risk of
Pseudomonas aeruginosa
i  f
 r i
Yes No
Start antibiotics and 
consider local epidemiology
t rt ti i ti   
i r l l i i l
2 anti-Pseudomonas
aeruginosa coverage
Anti-Pseudomonas
r i r
Re-assessment at 48–72 hours- t t  r
Fig. 3. Flow diagram for guidance
of initial management decisions for
patients with suspected ventilator-
associated pneumonia (VAP)—the
‘Tarragona approach’. Reproduced
with permission from Vidaur et al.
[7]. MRSA, methicillin-resistant
Staphylococcus aureus.
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Fig. 4. Flow diagram for guidance
of reassessment of patients with
ventilator-associated pneumonia
(VAP) after 48–72 h according to
clinical response and microbiologi-
cal cultures. Reproduced with per-
mission from Rello & Diaz [5].
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CONCLUSION
Immediate administration of adequate antibiotic
therapy is critical to improving survival in
patients with VAP. At the same time, appropriate
antimicrobial stewardship includes not only lim-
iting the use of inappropriate agents in patients
with VAP, but also improving our ability to
diagnose and exclude infection in the ICU setting
in order to avoid administering antibiotics to
patients without infection. De-escalation is a
further approach to such stewardship whereby
initial antibiotic therapy is narrowed so as to
optimise patient outcomes while avoiding the
consequences of unnecessary antibiotic treatment
[17].
Non-invasive clinical and more or less invasive
bacteriological approaches to the identiﬁcation of
patients with genuine infection and the guidance
of antibiotic therapy have each been proposed.
Direct examination of distal pulmonary samples
certainly helps in the selection of initial antibiotic
therapy for VAP, in addition to conﬁrming the
actual diagnosis of nosocomial pneumonia. In the
event that one or several speciﬁc aetiological
agents are identiﬁed by reliable diagnostic tech-
niques, such as BAL and quantitative cultures,
optimal antibiotic treatment can be selected in
light of the susceptibility patterns of the causative
pathogens without resorting to broad-spectrum
drugs or risking inappropriate treatment. There-
fore, every possible effort should be made to
obtain from each patient clinically suspected of
having developed VAP, before new antibiotics
are administered, reliable pulmonary specimens
for direct microscopic examination and quantita-
tive cultures. The results of such examinations
should be evaluated in conjunction with a careful
assessment of the clinical response to therapy.
Where initial therapy must be selected empiric-
ally, decisions are dependent on a detailed and
up-to-date understanding of pathogens causing
VAP locally. Such knowledge can only be
achieved if high-quality microbiological surveil-
lance information is readily available and
communication between microbiologists and cli-
nicians is ﬂuid.
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